CARsgen Therapeutics opens new U.S. cGMP facility for CAR T production
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Subscribe To Our Newsletter & Stay Updated